Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Recurrence

Thrombosis

Venous Thrombosis

Hemorrhage

Pulmonary Embolism

Embolism

Thromboembolism

Venous Thromboembolism

Embolism and Thrombosis

Vascular Diseases

Lung Diseases

Respiratory Tract Diseases

Anticoagulants

All Drugs and Chemicals

Fibrinolytic Agents

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Heparin

Calcium heparin

Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously

Dalteparin administered subcutaneously daily

Abelacimab

Dalteparin 200 IU/kg/day followed by 150 IU/kg/day

Nancy Widener

Deb Freedholm

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. Patients with intact GI and GU cancer have increased bleeding risk with oral direct anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc) administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

Itreas

Anthos Therapeutics, Inc.

Anti-Infective Agents

Amino Acids

Apixaban

Factor Xa Inhibitors

Antithrombins

Antithrombin III

Protease Inhibitors

Serine Proteinase Inhibitors

HIV Protease Inhibitors

Enzyme Inhibitors

Serine

Nancy Weidner

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. The two most common treatments today are low molecular weight heparin (LMWH) and direct anticoagulants (DOACs), in which each has limitations. DOACs are administered orally and are seen as a more convenient alternative though associated with bleeding risk; further, some cancer patients have difficulty swallowing or develop vomiting which leads to unpredictable pharmacodynamic effects with oral therapy. The ANT-007 study will compare treatment with abelacimab monthly administration to apixaban twice daily administration over a 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Fluorides

Clevudine

Antiviral Agents

Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.

Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT

18F-FMAU

Laboratory Biomarker Analysis

Multiparametric Magnetic Resonance Imaging

Positron Emission Tomography

Ultrasound

Hossein Jadvar, MD

This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.

PRIMARY OBJECTIVES:

I. To perform a prospective clinical imaging evaluation of 18F-FMAU PET/CT in addition to multiparametric magnetic resonance imaging (mpMRI) and standard transrectal ultrasound (TRUS)-guided 12-core biopsy for detection and localization of primary tumor in 40 men with suspected prostate cancer based on elevated/rising prostate specific antigen level, abnormal digital rectal exam, or those with prior negative standard biopsy who are now returning for a standard of care follow-up.

II. To examine the associations between the PET derived imaging parameters, serum PSA, mpMRI parameters (apparent diffusion coefficient \[ADC\], Ktrans) and the biopsy histopathology parameters.

OUTLINE:

Patients receive radiotracer F 18 d-FMAU intravenously (IV) over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.

After completion of study treatment, patients are followed up at 24-96 hours.

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer

Standard descriptive methods will be used to summarize the data collected: means, standard deviations, ranges, and confidence intervals (or medians, quartiles), contingency tables, histograms, correlation coefficients (Pearson or Spearman) and scatter plots. The scatter plots and correlations between each of the histopathology parameters and the imaging parameters will be examined to better understand the relationships.

National Cancer Institute (NCI)

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

University of Southern California

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	NCT05171075	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Dalteparin	18 Years -	Anthos Therapeutics, Inc.
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE	NCT05171049	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Apixaban	18 Years -	Anthos Therapeutics, Inc.
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer	NCT02809690	Prostate Neopla...	CAT 18F-FMAU Laboratory Biom... Multiparametric... Positron Emissi... Ultrasound	18 Years -	University of Southern California
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE	NCT05171049	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Apixaban	18 Years -	Anthos Therapeutics, Inc.
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	NCT05171075	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Dalteparin	18 Years -	Anthos Therapeutics, Inc.

Spots Global Cancer Trial Database for cat

Every month we try and update this database with for cat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cat

Every month we try and update this database with for cat cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.